Research at Wells Medicine

Learn about ketamine research conducted at Wells Medicine

Wells Medicine is working with Baylor College of Medicine and the University of Pittsburgh to conduct research on ketamine infusion therapy. These studies are important for developing our understanding of mental health conditions and ketamine therapy for mood disorders.

Wells Medicine provides a connection point between our research partners and interested patients. Patient relationships with Wells Medicine remain the same regardless of study participation.

BCM placeholder
Shield UnivPittsburgh 3color

In addition to the details below, information on these studies can also be found on the Baylor College of Medicine website.

IV Ketamine with Digital Therapy Exercises

remote, year-long study


Eligibility

  • Ages 18-80
  • Receiving IV ketamine with Wells Medicine for depressive symptoms
  • Patient is pursuing an initial series of ketamine infusions. Those new to ketamine or returning after a break are eligible
  • Completion of digital onboarding prior to first infusion


Reasons for Consideration

  • Compensation up to $650-$750
  • Participation (excluding ketamine infusion appointments) is remote and can be done from anywhere
  • Enhanced clinical monitoring of your symptoms through the study assessments
  • Chance of getting free access to a portable digital treatment that may extend the duration of your depression relief and help you get the most of your ketamine treatments
  • Contribution to knowledge of how to help people like yourself


Exclusions

  • Psychosis
  • Severe substance abuse

IV Ketamine with EEG Monitoring

in-person study, includes meetings with research team


Eligibility – MDD (Major Depressive Disorder)

  • Ages 21-55
  • Receiving IV ketamine with Wells Medicine for a current or past diagnosis of depression
  • Patient is receiving maintenance infusions or pursuing a series of ketamine infusions. Those new to ketamine or returning after a break are eligible
  • Completion of in-person onboarding prior to first infusion


Eligibility – TRD (Treatment-Resistant Depression)

  • Ages 21-55
  • Patient has tried at least one antidepressant in the past
  • Receiving IV ketamine with Wells Medicine for a current or past diagnosis of depression
  • Patient is pursuing a series of ketamine infusions. Those new to ketamine or returning after a break are eligible
  • Completion of in-person onboarding prior to first infusion


Reasons for Consideration

  • Compensation up to $250 (MDD patients) or $450 (TRD patients)
  • Uber ride to first infusion (MDD patients) or first and fourth infusions (TRD patients)
  • Evaluation and consultation with a psychiatrist
  • Bloodwork
  • Contribution to knowledge of how ketamine helps people like yourself


Exclusions

  • Psychosis
  • Bipolar disorder
  • Schizophrenia
  • Pregnancy

Next Steps


Contact us if you’d like to learn more about our work with research partners. Reach us by phone call, email, text, or contact form submission:

Contact Us